Observational studyDiabetes, obesity & metabolism2026
Mental health changes after 4 months of weight loss treatment with the glucagon-like peptide-1 analogue liraglutide 3.0 mg.
Observational study in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Neuropsychiatric Outcomes Associated with GLP-1 Receptor Agonists in Adults with Overweight or Obesity: A Systematic Review.Brain sciences · 2026Review
- Mental health changes after 4 months of weight loss treatment with the glucagon-like peptide-1 analogue liraglutide 3.0 mg.Diabetes, obesity & metabolism · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveThis observational study examined changes in mental health and wellbeing after 4-months liraglutide 3.0 mg treatment in patients with obesity and explored associations with weight loss.
methodsWe included 98 patients with obesity treated with liraglutide 3.0 mg. The Hospital Anxiety and Depression Scale (HADS: total score 0-42; depression/anxiety subscales 0-21), OBESI-Q psychological wellbeing (0-100) and anthropometrics were assessed at baseline and 4-month follow-up. Analyses included the full sample and subgroups with poor versus good baseline mental health.
resultsBody weight decreased after 4 months (-5.8%, p < 0.001). HADS total, depression, and (in trend) anxiety scores slightly decreased (-1.7 [95% confidence interval [CI] -3.2; -0.1, p < 0.05]; -1.0 [95% CI: -1.9; -0.1, p < 0.05] and -0.7 [95% CI: -1.5; 0.1, p = 0.095]). OBESI-Q psychological wellbeing scores increased (4.3 [95% CI: 0.8; 7.8, p < 0.05]). Mental health improvements occurred mainly in patients with poor baseline mental health. Weight loss occurred regardless of initial mental health. Anthropometrics changes were associated with changes in mental health and psychological wellbeing either significantly or in trend.
conclusionLiraglutide treatment was associated with weight loss without adverse mental health changes. Mental health benefits may be seen especially in those initially impaired. Weight loss was irrespective of baseline mental health status, suggesting liraglutide weight loss treatment effectiveness even in the presence of impaired mental health.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.